Seattle Genetics (SGEN) is the developer of antibody treatments for cancer. Today it has received a new patent which will extend its proprietary rights to its lead drug brentuximab vedotin, indicated for Hodgkin’s disease until at least 2025.
Seattle Genetics Adds Patent to 2025
Posted using ShareThis
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment